The first clinical trial has demonstrated that a novel “photoswitch” medication has shown signs of restoring light sensitivity in patients with severely damaged retinas. Scientists from the University of Adelaide and the University of Washington successfully conducted the first pilot human testing of this new type of drug. Operating at the molecular level, the medication forces the remaining, yet dysfunctional, cells in the eye to send visual signals to the brain when exposed to light.
The study targeted retinitis pigmentosa—a genetic disorder that causes dysfunction in the retina’s light-detecting cells and leads to progressive blindness. Currently, treatment options for the late stages of the disease are extremely limited. The researchers discovered that after injecting the small molecule into the eye, a portion of the damaged cells was revitalized and regained the ability to perceive light, even in conditions where normal receptors had already been completely lost.
According to the study’s lead author, Professor Robert Casson, unlike gene therapy, which focuses on specific mutations, this approach could be used to treat many different forms of retinal degeneration and, furthermore, eliminates the need for genetic modification.
The treatment proceeded without complications, and no serious adverse events were reported in patients. Beyond safety testing, the first positive biological signals were also detected. Specifically, several participants demonstrated short-term improvement during visual tests, and one patient noticed enhanced light perception just two days after the injection. Moreover, brain imaging confirmed that activity in the visual cortex increased following the treatment.
The findings of the study were published in the prestigious scientific journal Nature Medicine. According to the authors, despite the promising initial data, a larger-scale Phase II trial is already underway to definitively confirm the drug’s efficacy.
